News
Events
Press Releases
Careers
Contact Us
Home
About Us
Overview
Management
Board of Directors
Scientific Advisory Board
Careers
Product
Overview
RIZAPORT
®
Tadalafil
Loxapine
Montelukast
More Products
R&D Services
Overview
VersaFilm
VetaFilm
Services
Manufacturing Services
Overview
Manufacturing & Packaging
Services
Partnering
Overview
Trade Shows
BD Contacts
Investors
Overview
Shareholder Reports
Corporate Governance
Press Releases
Stock Price
Presentations
Regulatory Filings
XBRL Files
Analyst Coverage
Videos
RSS Feeds
IR Contact
Home
About Us
Overview
Management
Board of Directors
Scientific Advisory Board
Careers
Product
Overview
RIZAPORT<sup>®</sup>
Tadalafil
Loxapine
Montelukast
More Products
R&D Services
Overview
VersaFilm
VetaFilm
Services
Manufacturing Services
Overview
Manufacturing & Packaging
Services
Partnering
Overview
Trade Shows
BD Contacts
Investors
Overview
Shareholder Reports
Corporate Governance
Press Releases
Stock Price
Presentations
Regulatory Filings
XBRL Files
Analyst Coverage
Videos
RSS Feeds
IR Contact
INTELGENX
Home
>
Investors
>
Press Releases
INTELGENX
Home
>
Investors
>
Press Releases
Normal
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
IntelGenx Closes $3.5 Million Public Offering
December 16, 2013
IntelGenx Announces Public Offering of $3,500,000 of Common Stock
December 12, 2013
IntelGenx Reports Q3, 2013 Results and Corporate Development Highlights
November 8, 2013
IntelGenx Corp. Receives Buprenorphine/Naloxone Sublingual Film Product Patent Infringement Complaint
August 26, 2013
IntelGenx Receives Paragraph IV Certification Letter on Submission of ANDA for Forfivo XL®
August 22, 2013
IntelGenx Reports Q2, 2013 Results and Corporate Development Highlights
August 8, 2013
IntelGenx Announces Submission of ANDA for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction
July 22, 2013
IntelGenx Announces FDA Acceptance of New Drug Application for Anti-Migraine VersaFilm(TM) Oral Film Product
June 18, 2013
IntelGenx Reports Q1, 2013 Results and Provides Operational Update
May 14, 2013
IntelGenx Secures Leadership Succession
April 24, 2013
IntelGenx submits New Drug Application for Anti-Migraine VersaFilm(TM)
March 27, 2013
IntelGenx Reports 2012 Annual Results and Provides Operational Update
March 18, 2013
IntelGenx to Present at Roth Capital Partners 25th Annual Growth Stock Conference
March 18, 2013
Home
About Us
Overview
Management
Board of Directors
Scientific Advisory Board
Careers
Product
Overview
RIZAPORT
®
Tadalafil
Loxapine
Montelukast
More Products
R&D Services
Overview
VersaFilm
VetaFilm
Services
Manufacturing Services
Overview
Manufacturing & Packaging
Services
Partnering
Overview
Trade Shows
BD Contacts
Investors
Overview
Shareholder Reports
Corporate Governance
Press Releases
Stock Price
Presentations
Regulatory Filings
XBRL Files
Analyst Coverage
Videos
RSS Feeds
IR Contact
Shareholder Tools
Financial Reports
E-mail Alerts
RSS News Feeds
About us
Overview
Management
Board of Directors
Careers
Product
Overview
RIZAPORT
®
Tadalafil
Loxapine
Montelukast
More Products
R&D Services
Overview
VersaFilm
®
Services
Manufacturing Services
Overview
Film Manufacturing
Services
Partnering
Overview
Investors
Overview
Financial Reports
Corporate Governance
Press Releases
Stock Price
Presentations
Regulatory Filings
Analyst Coverage
IR Contact
More Links
Facebook
Twitter
Linkedin
Contact us
Careers
Email Signup
RSS Feeds
© Copyright 2019. IntelGenx Corp. All Rights Reserved.
Terms of Service
Privacy
Contact Us
Powered By Q4 Inc.
5.23.3.1